Cardio Risk of Acute Schizophrenia Olanzapine Duke
Status:
Withdrawn
Trial end date:
2010-02-01
Target enrollment:
Participant gender:
Summary
Primary Objective: To compare added metformin and/or added simvastatin versus no intervention
in reducing or eliminating increased cardiovascular risk (as estimated by elevation in
non-HDL cholesterol levels) during the treatment of schizophrenia with olanzapine.
Secondary Objective(s): To compare added metformin and/or added simvastatin versus no
intervention in reducing or eliminating increased cardiovascular risk (as estimated by
elevation in triglyceride levels) during the treatment of schizophrenia with olanzapine. To
compare added metformin and/or added simvastatin versus no intervention in reducing or
eliminating increased cardiovascular risk (as estimated by C-reactive protein levels) during
the treatment of schizophrenia with olanzapine